Business
Update on Phase III GY004 trial for cediranib
Update on Phase III GY004 trial for cediranib.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n RNS Number : 8940F\n AstraZeneca PLC\n 12 March 2020\n \n \n \n \n \n \n \n 12 March 2020 07:00 GMT\n \n \n \n \n \n Update on Phase III GY004 trial for cediranib added toLynparza in platinum-sensitive relapsed ovarian cancer\n \n \n \n \n \n The trial did not meet the primary endpoint of progression-\nfree survival vs. platinum-based chemotherapy\n \n \n \n \n \n AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), that examined primarily the efficacy and safety of the potential new medicine cediranib added to Lynparza (olaparib) versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. Ovarian cancer is the eighth most common cause of death from cancer in women worldwide.\n \n \n \n \n \n The trial did not meet the primary endpoint in the intent-to-treat (ITT) population of a statistically significant improvement in progression-free survival (PFS) with cediranib added to Lynparza versus platinum-based chemotherapy. Cediranib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor, which blocks the growth of blood vessels supporting tumour growth.\n \n \n \n \n \n José Baselga, Executive Vice President, Oncology R&D, said: \"Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer. We will work closely with NRG Oncology and the NCI to review the full results to inform our ongoing research.\"\n \n \n \n \n \n Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: \"Ovarian cancer is one of the most difficult tumours to diagnose and treat early. AstraZeneca, MSD and our partners will continue to explore ways to help patients through our joint clinical trial development programme.\"\n \n \n \n \n \n The safety and tolerability profiles observed in GY004 were generally consistent with those known for each medicine. \n \n \n \n \n \n The NCI and NRG Oncology will present the full data at a forthcoming medical meeting.\n \n \n &nbs...